NCT04948333 2026-03-18Asciminib Treatment Optimization in ≥ 3rd Line CML-CPNovartisPhase 3 Completed199 enrolled 13 charts
NCT06082635 2025-05-18TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Shenzhen TargetRx Co., Ltd.Phase 3 Active not recruiting321 enrolled